appropriate Vacquinol
termed Vacquinol
glioblastoma cells
Synthetic chemical expansion of Vacquinol
IP protected small molecule Glioblastoma multiforme
massive vacuolization
complete cell death
aggressive form of brain cancer
examined cell types
brain exposure measurements
increased vulnerability of GSCs
unanticipated vulnerability of GSCs
GLP toxicological
tumor cells
animal models of human GBM
commercialization potential
possible commercialization
development stage
vacuolization results
development plan
IP protection
induction of massive macropinocytosis
times greater potency
aggressive available therapy
GMP-compatible stereo-selective synthesis
intellectual property
cytoplasmic membrane rupture
patent
marginal life expectancy
oral bioavailability
amending composition of matter
cytotoxicity
survival
efficacy
competing compounds
phase
isomer
Karolinska Institutet Innovations AB
current chemotherapy
favorable pharmacokinetics
new treatment
disease
discovery
clinical trials
different patients
astrocytes
preclinical characteristics
delicate structure activity relationship
viability
optimized dosage regimen
Validation
cellular mechanism
order